Aids in the diagnosis of paraneoplastic neurological syndromes associated with ANNA-1 (Hu), ANNA-2 (Ri), PCCA-1 (Yo), PCCA-Tr/DNER, amphiphysin, CV2.1, and SOX1 antibodies. Serum is the preferred specimen; see Paraneoplastic Reflexive Panel (3002929).
Semi-Quantitative Indirect Fluorescent Antibody/Qualitative Immunoblot
New York DOH Approval Status
Transfer 2 mL CSF to an ARUP Standard Transport Tube. (Min: 1 mL).
Contaminated, heat-inactivated, hemolyzed, or lipemic specimens
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month
|3002257||CV2.1 Screen by IFA with Reflex to Titer, CSF||Less than 1:1|
|2010841||Paraneoplastic Antibodies (PCCA/ANNA) by IFA with Reflex to Titer and Immunoblot, CSF||
|3004510||Amphiphysin Antibody IgG, CSF||Negative|
|3002885||SOX1 Antibody, IgG by Immunoblot, Serum||Negative|
Refer to report
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Purkinje Cell (PCCA) antibody and Neuronal Nuclear (ANNA) antibody IgG are screened by IFA. If the IFA screen is indeterminate, then a Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot will be added. If the IFA screen is positive at 1:1 or greater, then a PCCA/ANNA antibodies titer and Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot will be added. Additional charges apply.
If CV2.1 Antibody IgG Screen by IFA is positive, then CV2.1 Antibody IgG Titer by IFA will be added. Additional charges apply.
86255 x2; 84182 x2; if reflexed add 86256 and/or 84182 x4; if reflexed add 86256
|Component Test Code*||Component Chart Name||LOINC|
|2010842||Paraneoplastic Abs (PCCA/ANNA) IgG, CSF||14247-1|
|3002259||CV2.1 Ab IgG Screen, CSF||53707-6|
|3002904||SOX1 Antibody, IgG by Immunoblot, CSF||94383-7|
|3004511||Amphiphysin Antibody, CSF||57750-2|